Friedrich Graf Finckenstein

Friedrich Graf Finckenstein

Company: Iovance Biotherapeutics

Job title: CMO


Clinical Success of the Iovance TIL Technology Platform in Solid Tumors 10:30 am

• Highlight advantages of polyclonal TIL MOA for solid tumors • Review positive clinical data for TIL in metastatic melanoma and other solid tumor types • Explore next-generation approaches: combinations and genetically modified TILRead more

day: Day Two

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.